Product News and Clinical Trial Results
DFINE, Inc. offers advanced treatment for immediate pain relief and improved quality of life for patients suffering from spinal fractures due to osteoporosis
May 24, 2011 Source: DFINE, Inc
While conventional medical treatments, for vertebral compression fractures caused by osteoporosis include bed rest, stabilization (or bracing) and pain medications, it does not work for all patients. A new technology, known as radio frequency targeted vertebral augmentation™ (RF-TVA), delivers immediate relief to patients who have previously been told there is no option beyond bed rest in hopes that the bone will heal on its own.
Aspirin that works in half the time released by Bayer
May 23, 2011 Source: Medical News Today
Bayer AG has introduced a reformulated aspirin that works twice as fast as existing ones, using what it called Pro-Release technology which reduces the aspirin particles into micro-particles. The micro-particles are about one tenth of the typical particle size, hence they dissolve more easily and arrive at the site of pain more rapidly.
Study characterizes extractability properties of once-daily extended-release hydromorphone
May 20, 2011 Source: Covidien
Results of hardness testing demonstrated that once-daily hydromorphone ER withstood significantly more force before cracking than the active comparator. Milling the tablets yielded approximately 30 percent of active ingredient versus approximately 65 percent from the active comparator. In a separate study, once-daily hydromorphone ER was shown to provide predictable, consistent 24-hour blood plasma levels of hydromorphone at steady state.
Progenics announces results of methylnaltrexone Phase 3 safety study in chronic, non-malignant pain patients
May 20, 2011 Source: Progenics Pharmaceuticals Inc.
Progenics Pharmaceuticals, Inc. today provided analyses of safety and efficacy endpoints from the 1,034-patient, one-year Phase 3 safety study of methylnaltrexone bromide subcutaneous injection in non-malignant pain patients with opioid-induced constipation. At a fixed dose of 12 mg, the drug was shown to be generally safe and well tolerated, with a safety profile similar to that from a previously reported, shorter-duration efficacy study in non-malignant pain patients.
Xgeva shown to significantly delay bone pain
May 17, 2011 Source: Reuters
A clinical trial of Amgen Inc's bone drug Xgeva found that it can significantly delay the time it takes for prostate cancer to cause bone pain -- a finding the company believes will help boost the drug's market potential. Amgen said in December that monthly injections of Xgeva, also known as denosumab, added 4.2 months, compared with placebo injections, to the length of time patients lived without their cancer spreading.
Existing drug treatment reduces pain in young sickle cell anemia patients
May 12, 2011 Source: UT Southwestern Medical Center
A cancer drug already used to treat adults and school-age children with sickle cell anemia is safe and significantly reduces pain and other complications of the disease in children as young as 9 months, according to a national study. Pediatric researchers and academic medical centers say hydroxyurea should be offered to all young children with sickle cell anemia, regardless of disease severity and clinical symptoms.